Shanghai Henlius Biotech,Inc. (“Shanghai Henlius”) has completed the phase I clinic study of recombinant humanized anti-HER2 monoclonal antibody for injection (“New Drug”). The results of phase I clinic trial confirmed that: the New Drug is safe and has same effectiveness of Herceptin^®. Shanghai Henlius has officially started the phase III clinic trial of the New Drug at present.

　　On the other hand, the first innovative bio-modified monoclonal antibody HLX07 drug under independent research and development of Shanghai Henlius has obtained approvals of clinical trial in mainland China, Taiwan and the United States. The registration of such drug in those countries and regions realized the international development strategy of the products of research and development. In addition to the innovative monoclonal antibody drugs under its independent development, Shanghai Henlius has added two new innovative monoclonal antibody drugs by entering into licensed cooperation with a renowned international biomedical enterprise, thus further enhancing its competitiveness in anti-tumor therapeutic area.